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SINTESIS, PENCIRIAN DAN KAJIAN SITOTOKSIK BAGI 
BEBERAPA TERBITAN BARU 1,2,4-TRIAZOL  
 
ABSTRAK 
Dalam kajian ini, 36 sebatian baru 1,2,4-triazol dengan sistem gelang mono 
dan terlakur telah disintesis dan dicirikan. Sistem mono bagi terbitan 1,2,4-triazol 
mempunyai kumpulan yang berbeza terikat pada gelang triazol. Sistem mono yang 
pertama menunjukkan empat sebatian garam piridinium dan bes Schiff terikat pada 
gelang triazol manakala sistem mono yang kedua menunjukkan 24 sebatian garam 
piperidinium dan bes Schiff terikat pada gelang triazol. Sistem terlakur bagi terbitan 
1,2,4-triazol termasuk tiga sebatian dengan gelang terlakur triazol-oksadiazol dan 
lima sebatian dengan gelang terlakur triazol-triazol. Kesemua sebatian ini telah 
dicirikan menggunakan spektroskopi Inframerah Transformasi Fourier (FT-IR) dan 
Resonan Nuklear Magnetik (NMR) dan analisa unsur karbon, hidrogen dan nitrogen 
(CHN). Beberapa sebatian telah dipilih untuk ujian sitotoksik dalam mencari agen 
anti kanser yang berpotensi, terutamanya untuk sel kanser payudara manusia (MCF-
7) dan sel kanser kolon manusia (HCT 116). Sebanyak 35 sebatian yang terdiri 
daripada sembilan bahan perantara dan 26 hasil akhir telah dipilih untuk asai 
sitotoksik. Nilai IC50 bagi beberapa sebatian yang tidak dapat ditentukan dalam asai 
MTT terhadap sel kanser MCF-7 atau HCT 116 dianggap tidak aktif. Asai MTT 
terhadap MCF-7 menunjukkan hanya sebatian 6A dan 7B sahaja yang mempunyai 
aktiviti sederhana dengan nilai IC50 masing-masing iaitu 38 and 53 µM. Lapan 
sebatian lain menunjukkan aktiviti anti-proliferasi yang sederhana lemah manakala 
enam sebatian lain menunjukkan aktiviti yang lemah. Asai MTT terhadap HCT 116 
menunjukkan hanya sebatian 9A2-iii dan 9B2-iii yang melihatkan kesan sitotoksik 
 xx 
yang sederhana dengan nilai IC50 masing-masing iaitu 42 dan 56 µM. Tiga sebatian 
lain menunjukkan kesan perencatan yang kurang ke atas proliferasi sel dan lapan 
sebatian yang lain menunjukkan aktiviti yang lemah dengan nilai  IC50 > 110. 
Keempat-empat terbitan baru 1,2,4-triazole yang berpotensi sebagai agen anti-
proliferatif yang baik ialah sebatian 6A (IC50= 38 µM) dan 7B (IC50= 53 µM) 
terhadap sel kanser payudara manusia (MCF-7) sementara sebatian 9A2-iii (IC50= 42 
µM) dan 9B2-iii (IC50= 56 µM) terhadap sel kanser kolon manusia (HCT 116).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xxi 
SYNTHESIS, CHARACTERISATION AND CYTOTOXICITY STUDY OF 
SOME NEW 1,2,4-TRIAZOLE DERIVATIVES 
 
ABSTRACT 
In this study, 36 new 1,2,4-triazole compounds with mono and fused ring 
system have been synthesised and characterised. The mono system of 1,2,4-triazole 
derivatives have different moieties attached to the triazole ring. The first mono 
system showed four compounds of a pyridinium salt and a Schiff base moiety 
attached to the triazole ring, while the second mono system showed 24 compounds of 
a piperidinium salt and a Schiff base moiety attached to the triazole ring. The fused 
system of 1,2,4-triazole derivatives include three compounds with the triazole-
oxadiazole fused ring and five compounds with the triazole-triazole fused ring. All 
these compounds were characterised using Fourier Transform Infrared (FT-IR) and 
Nuclear Magnetic Resonans (NMR) spectroscopy and carbon hydrogen nitrogen 
(CHN) elemental analysis. Some of the compounds were selected for cytotoxicity 
test in the search for potential anticancer agents, in particular for human breast tumor 
cells (MCF-7) and human colorectal tumour (HCT 116) cell. 35 compounds 
consisting of nine intermediates and 26 final compounds were tested for cytotoxicity 
assay. The IC50 for some of the compounds which could not be determined in the 
MTT assay against MCF-7 or HCT 116 cells were considered inactive. The MTT 
assay findings against MCF-7 showed that only compounds 6A and 7B indicated 
moderate activity of IC50 38 and 53 µM, respectively. Eight other compounds 
showed moderate to weak anti-proliferation activity while six other compounds 
showed weak activity. The MTT assay against HCT 116 showed that only 
compounds 9A2-iii and 9B2-iii demonstrated moderate cytotoxic effect with IC50 42 
 xxii 
and 56 µM, respectively. Three other compounds demonstrated lesser inhibitory 
effect on cell proliferation while eight other compounds showed poor activity with 
the IC50 of > 110. These four new 1,2,4-triazole derivatives which showed potentials 
to become promising anti-proliferative agents are compounds 6A (IC50= 38 µM) and 
7B (IC50= 53 µM) against human breast tumor cells (MCF-7) while 9A2-iii (IC50= 42 
µM) and 9B2-iii (IC50= 56 µM) against human colorectal tumour cells (HCT 116).  
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CHAPTER 1 
INTRODUCTION 
1.1 Background of the research work  
 In the field of pharmaceutical organic chemistry, research is concentrated 
towards the introduction of new and safe therapeutic agents of clinical importance. 
Recently, the 5-membered ring heterocyclic compounds have proved their 
importance as being the centre of the biological activities (Kashyap et al., 2011). The 
nitrogen containing heterocycles are found in abundance in most of the medicinal 
compounds. Starting with imidazole as an important moiety of the medicinal agent, 
research work has led to the introduction of triazole which is an isostere of 
imidazole, in which the carbon atom of imidazole is isosterically being replaced by 
nitrogen (Bele and Singhvi, 2011).  
 Triazole is a 5-membered ring compound which contains two carbon and three 
nitrogen atoms. According to the position of the nitrogen atoms, the 5-membered 
triazole ring exists in two isomeric forms known as 1,2,3-triazole and 1,2,4-triazole, 
the former being known as osotriazole, and the latter as triazole. However, 1,2,4-
triazole exists in two tautomeric forms of 1H and 4H-1,2,4-triazole (1), which is 
characterised by the position of the hydrogen (Finar, 1975, Singh and Chouhan, 
2014, Shneine and Alaraji, 2016). 
 
N
N
N
H
N
N
N
H
1,2,3-Triazole 1H-1,2,4-Triazole
N
N
N
H
1
2
34
5
1
2
34
5
1
2
34
5
4H-1,2,4-Triazole
(Osotriazole)
tautomer
1(Triazole)  
 2 
 The discovery of 1,2,4-triazole ring represents an interesting class of 
compounds with promising biological activities (Valverde and Torroba, 2005) as 
antibacterial agent (Jayachandran et al., 2005; Matthew et al., 2007; Shaker, 2006; 
Swamy et al., 2010, ), antimicrobial agent (Udupi et al., 2000a; Udupi et al., 2000b; 
Foroumadi et al., 2003; Hussain et al., 2008; Sharma et al., 2010; Upmanyu et al., 
2011; Patil et al., 2013), anti-mycobacterial (Klimesová, et al., 2004), anticonvulsant 
(Plech et al., 2014), antifungal ((Mali et al., 2009, Luo and Hu, 2006), antidepressant 
(Düğdü et al., 2014, Chelamalla et al., 2012, Wakale et al., 2013) and anti-
tuberculosis (Kaplancikli et al., 2005, Nandha et al., 2013). 
 Among these heterocycles, the mercapto- (2), thione- (3) and dithione- (4) 
substituted 1,2,4-triazole ring systems have been well studied and so far a variety of 
biological activities have been reported for a large number of their derivatives. This 
1,2,4-triazole system with sulphur substituted compounds represents promising 
biological activities due to the presence of the NCS (=N-C-S) moiety in the 
compounds (Shaker, 2006). 
 
 The mercapto-1,2,4-triazoles, 2 are of great utility in the organic chemistry 
synthesis because in the presence of various reagents, these compounds undergo 
different types of reactions to yield interesting fused heterocyclic compounds such as 
triazolothiadiazolones (5), triazolothiadiazolothiones (6), triazolothiadiazines (7) and 
triazolothiadiazinones (8) (Holla et al., 2001; Abdel-Rahman et al., 2011; Siddiqui et 
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al., 2015). Compounds of triazoles fused to thiadiazines or thiadiazoles rings are also 
being incorporated into a wide variety of therapeutically important compounds, 
possessing a broad spectrum of biological activities (El Shehry et al., 2010, El-Sayed 
et al., 2010, Kamel and Abdo, 2014). 
 
 In the field of agrochemicals, the most common systems are generally 1,2,4-
triazoles fused to pyridines (9), pyridazines (10), pyrimidines (11) and pyrazines 
(12). Pyridine heterocyclic moiety plays a vital role in the development of medicinal 
agents which are present in many products such as drugs, vitamins, food, plant dyes, 
adhesives and herbicides (Katrizky et al., 1996; Mohamed, 2010).  
 
 Several studies have also been reported on the fused 1,2,4-triazoles derivatives 
with other heterocyclic moieties such as triazole ring, 13 (Othman et al., 2014), 
oxadiazole ring, 14 (Somani and Shirodkar, 2009, Deshmukh et al., 2011) and 
thiazole ring, 15 (Erian et al., 2003, Andrew et al., 2008). Various thiazole 
derivatives are proven to be efficient for various diseases. They showed good 
physiological activities and are considered as good therapeutic agents such as anti 
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tubercular agents (E1-Shaaer et al., 1998, Siddiquia et al., 2011) and antimicrobial 
agents (Guzeldemirci and Kucukbasmac, 2010, Liaras et al., 2011). Furthermore, 
diverse chemotherapeutic activities have also been ascribed to fused 1,2,4-
triazolothiazole moieties as antimicrobial agents. 
 
 Schiff bases compounds have the imine or azomethine (–C=N–) functional 
group which is condensation products of the primary amines with carbonyl 
compounds. Schiff bases compounds have gained importance in medicinal and 
pharmaceutical fields due to their broad spectrum of biological activities. However, 
not many research work on the fused 1,2,4-trizole compounds with Schiff base 
moiety have been reported. This led to the formation of new ideas in the 
pharmacological and medicinal chemistry especially in the synthesis of 
therapeutically interesting molecules with better pharmacological functions for 
anticancer activity. Schiff bases of fused 1,2,4-triazoles have been found to possess 
extensive biological activities (Bekircan and Bektas, 2006; Bagihalli et al., 2008; Li 
et al., 2012, Farghaly et al., 2015; Gabr et al., 2015). 
 Cancer disease, a major worldwide problem is characterised by the 
proliferation and spreading of the abnormal cells. Therefore, the discovery and 
development of new potent and selective anticancer drugs are of high importance in 
modern cancer research. In spite of a large number of chemotherapeutic drugs 
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available for medical usage, the increasing resistance made it necessary to continue 
the search for new potential anticancer drugs. 
1.2 Problem statement 
 New findings have established the fact that fused 1,2,4-triazole ring contributed 
great significance in the field of medicinal chemistry due to their versatile biological 
properties (Asif, 2014). However, these types of derivatives targeting specifically on 
the anticancer activity have not been widely explored (Holla et al., 2002; Holla et al., 
2003; Demirbas and Uğurluoğlu, 2004a; Demirbas and Uğurluoğlu, 2004b; Sztanke 
et al., 2008; Bhat et al., 2009; Al-Issa, 2013, Hassan et al., 2013; Kamel and Abdo, 
2014). Since a large number of fused 1,2,4-triazoles derivatives have shown 
pharmacological properties as anticancer agents, this research work focused on the 
modification of 1,2,4-triazole scaffold into various bioactive structures and their 
subsequent evaluation for cytotoxicity activities focusing on the colon and breast 
cancer cell lines (HCT and MCF 7) which are two of the common cancers.  
1.3 Objectives 
The main objectives of this project are: 
1. To synthesise and characterise the mono system of 1,2,4-triazole derivatives 
which are divided into compounds with pyridinium salt and Schiff base moieties 
and compounds with piperidinium salt and Schiff base moieties.  
2. To synthesise and characterise the fused system of 1,2,4-triazole derivatives 
which are divided into compounds with triazole-oxadiazole ring and compounds 
with triazole-triazole ring.  
3. To evaluate the cyctotoxic activity of all these compounds on the colon and 
breast cancer cell lines.     
 6 
1.4 Scope of the Study 
 The research involved synthesizing some new 1,2,4-triazoles derivatives and 
characterisation work has been done using 1D and 2D NMR, FT-IR and CHNS         
elemental analysis. All these instruments are located at the School of Chemical 
Sciences. Samples for the anticancer work have been prepared and were sent to the 
Eman’s Lab at Eureka. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Compounds with 1,2,4-triazole core system 
 The discovery and development of new effective and selective anticancer drugs 
are of high importance in modern cancer researches (Ferlay et al., 2013). However, 
the fused 1,2,4-triazole compounds targeting specifically on the anticancer activity 
have not been widely explored. To date, only several studies on such compounds 
have been reported (Hou et al., 2011; Baviskar et al., 2012; Arul and Smith, 2014). 
Among the research work, the mercapto- and thione-substituted 1,2,4-triazole rings 
attached to a pyridine system have been of great interest due to the presence of the 
NCS (=N-C-S) moiety in the compounds (Shaker, 2006). 4-amino-5-(4-pyridyl)-4H-
1,2,4-triazole-3-thiol derivatives showed very promising results on anticancer 
activity. The two isomers of 4-amino-5-(4-pyridyl)-4H-1,2,4-triazole-3-thiol 
molecule, known as thiol, 16 and thione, 17 exist in equilibrium (Creanga et al., 
2010). The preparation of this 1,2,4-triazole derivatives produces two kinds of 
organic salts, 18 and 19.  (Ren and Jian, 2008). 
NN
N
NH2
SH
4-amino-5-(4-pyridyl)-4H-
1,2,4-triazole-3-thiol, 16
NN
N
NH2
S
H
N N
4-amino-3-(4-pyridyl)-1H-
1,2,4-triazole-5(4H)-thione, 17 
NN
N
NH2
S
potassium 4-amino-5-(4-pyridyl)-4H-
1,2,4-triazole-3-thiol, 18
NN
N
NH2
S
H
N HN
4-(4-amino-5-thioxo-1H-1,2,4-triazol-3-yl)-
pyridinium chloride, 19
K Cl
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 Preparation of 4-amino-5-(4-pyridyl)-4H-1,2,4-triazole-3-thiol via cyclisation 
reaction of potassium 2-isonicotinoylhydrazinecarbodithioate gave a mixture of 
1,2,4-triazole and its corresponding 1,3,4-oxadiazole derivatives, as shown in Figure 
2.1.  However, delicate work on the purification of this mixture afforded compound 
18 in good purity but in low yield (Creanga et al., 2010).  
potassium 
2-isonicotinoylhydrazinecarbodithioate
NHHN
S
S
N
O
K
NN
N
NH2
S
N
K
NN
O
S
N
KCyclization
1,2,4-triazole derivative
18
+
1,3,4-oxadiazole derivative
 
Figure 2.1: Cyclisation of 1,2,4-triazole and 1,3,4-oxadiazole derivatives 
 Iqbal et al. (1996) reported the synthesis of new 1,2,4-triazoles compounds, 3-
substituted thio-4-(2-phenylethyl)-5-(isomeric pyridyl)-1,2,4-triazoles, 21(a-c) and 
22(a-c) derivatives from 4,5-disubstituted-1,2,4-triazoles 20(a-c) using various 
isomers of pyridine carboxylic acid hydrazide with 2-phenylethyl isothiocyanate.  
NN
N
SAr
H
21(a-c)
NN
N
SAr
H
20(a-c)
NN
N
SAr
H
22(a-c)
COOH
Ar =
N N N
; ;
(a) (b) (c)  
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 Iqbal et al. (1997) continued to synthesize a new series of 4-(4-halopheny)-3-
(isomeric pyridyl)-1H-1,2,4-triazoles-3-thion derivatives, 23(a-c) through cyclisation 
reaction of 4-(isomeric pyridyl) thiosemicarbazide which was prepared from 4-
halophenyl isothiocyanates with isomers of pyridyl carboxylic acid hydrazide.  
NN
N
S
H
23(a-c)
N
X
a: 2-pyridyl; b: 3-pyridyl; c: 4-pyridyl
X: F, Cl, Br  
 Banachiewicz et al. (2000) has reported two new systems of 4,4'-(1,4-
phenylene)bis[5-(pyridin-4-yl)-4H-1,2,4-triazole-3-thiol] and 4,4'-(1,4-
phenylene)bis[5-(pyridin-2-yl)-4H-1,2,4-triazole-3-thiol], 24(a-b) via the 
condensation of N’-substituted amidrazones and p-phenylenediisothiocyanate.  
NN
N
S
H
24(a-b)
N
a: 2-pyridyl; b: 4-pyridyl
N N
N
S
H
N
 
 Zamani and his co-workers have conducted two independent studies in 2003 
and 2004. The first study reported on the synthesis and characterisation of some new 
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compounds, 25(a-c) without any biological or pharmacological activity work 
(Zamani and Faghihi, 2003). Later, other synthesis work on pyridyl and naphthyl 
substituted 1,2,4-triazole and 1,3,4-thiadiazole derivatives, 26(a-c), and their 
antimicrobial activity screening was reported (Zamani et al., 2004). 
NN
N
S
25(a-c)
N
CH3
a: 2-pyridyl; b: 3-pyridyl; c: 4-pyridyl
R: H(a-c); CH3(a-c); C2H5(a-c);
     CH2Ph(a-c); CH2COOH(a-c)
26(a-c)
a: 2-pyridyl; b: 3-pyridyl; c: 4-pyridyl
R
NN
N
S
N
R
R: H(a-c); CH3(a-c); CH2Ph(a-c)
 
 Zhang et al. (2008) reported two new series of  S-nucleosides of 5-(4-pyridyl)-
4-aryl-4H-1,2,4-triazole-3-thiols via direct glycosylation of 5-(4-pyridyl)-4-aryl-4H-
1,2,4-triazole-3-thiols 27(a-n) which gave the corresponding derivatives, 28(a-n). 
The removal of the protecting groups using ammonia gas in dry methanol afforded 
the final series, 29(a-n). All these compounds have been tested against three different 
type of anti-HIV-1, the reverse transcriptase (RT), protease (PR) and integrase (IN) 
activities but none of these compounds showed good anti-HIV activity. 
NN
N
R
SH
R: Ph(a); o-C2H5OPh(b); p-C2H5OPh(c); o-CH3OPh(d); p-CH3OPh(e); o-CH3Ph(f); m-CH3Ph(g); 
      p-CH3Ph(h); o-BrPh(i);  m-BrPh(j); p-BrPh(k);o-ClPh(l);  m-ClPh(m); p-ClPh(n);
N
NN
N
R
S
N
O
OAc
OAcAcO
OAc
NN
N
R
S
N
O
OH
OH
HO
OH
27(a-n) 28(a-n) 29(a-n)
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 Nadeem and Ashraf (2012) modified Zhang’s work using some novel Mannich 
bases to prepare the N‐nucleosides of 4‐amino‐5‐substituted‐1,2,4‐triazole‐3‐thiones 
whereby their in‐vitro antimicrobial activity was also examined. The original 
1,2,4‐triazoles molecules 30(a-j) portrayed lower antibacterial activity compared to 
the corresponding protected nucleosides 31(a-j) and the unprotected nucleosides 
32(a-j) against some selected bacteria. 
NN
N
NH2
SHR
R: 2-pyridyl(a); 3-pyridyl(b); 4-pyridyl(c); 4-CH2Ph(d); 3,4,5-triCH3OPh(e); 
4-FPh(f); 4-ClPh(g); 4-BrPh(h); 2-napthyl (i); 1-napthyl (j)
NN
N
NH2
S
O
OAc
OAcAcO
OAc
30(a-j) 31(a-j) 32(a-j)
NN
N
NH2
SR
O
OH
OHHO
OH
R
 
2.2 Schiff base 1,2,4-triazole derivatives 
 Recently, some well-known 1,3,4-oxadiazole and 1,2,4-triazole systems were 
developed by Bayrak et al. (2009). Some new Schiff base, 33(a-b) and Mannich base 
with an aliphatic cyclic amine such as morpholine or methyl piperazine, 35(a-c) 
compounds were prepared. The corresponding Mannich base of compound 34 was 
reported to possess some biological activities. 
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NN
N
N
S
N
33(a-b)
H
H
R
NN
N
N
S
N
H
NN
N
NH2
S
N
N N CH3
F
R
34
35(a-c)
R = 33a: F
R = 33b:
N
H
R = 35a:
N N CH3
R = 35b:
N O
N N CH3
R = 35c: NH CH2CH2
 
 Valentina et al. (2009) have synthesised compounds 36(a-e), the Schiff base of 
4-Amino-5-(4-hydroxyphenyl)-4H-1,2,4-triazole-3-thiol which showed good 
antioxidant activity. Moreover, Singh et al. (2010) have synthesised some new Schiff 
base of 4-amino-5-(4-pyridyl)-1,2,4-triazole-3-thiol compounds, 37(a-g) and their 
antibacterial activities have been reported against four kinds of well-known bacteria, 
S. aureus, E. coli, P. vulgaris and  K. pneumonia. However, all series showed mild 
antibacterial activity. 
NN
N
N
SH
N
37(a-g)
H
R = a: 4-OH, 3-OCH3; b: 2,4-Cl; c: 2,6-Cl;
       d: 2,4-Br; e: 2,6-Br; f: 2-OH; g: 4-N(CH3)2
R
NN
N
N
SH
36(a-e)
H
R = a:H; b: 3-OH; c: 2-Cl;
       d: 2-NO2; e: 3-NO2
HO
R
 
 The composition of 4-(substituted benzylidene amino)-5-(isomeric pyridyl)-
4H-1,2,4-triazole-3-thiols 38(a–p) were accomplished in a one-step reaction by 
Foroughifar et al. (2010) via reacting the corresponding substrates of 4-amino-5-
(isomeric pyridyl)-4H-1,2,4-triazole-3-thiols with various aromatic aldehydes in 
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refluxing acetic acid. All the derivatives obtained were used to synthesize of 
subsequent compounds of substituted triazolo[3,4-b][1,3,4]thiadiazines 39(a–p). 
NN
N
N
S
Ar
39(a-p)
Ar = 4-pyridyl; 3-pyridyl
X = H, 4-Me, 4-OMe, 3-Br, 2-Cl, 4-Cl, 2-NO2, 4-NO2
X
NN
N
N
SHAr
38(a-p)
H
X
H
OEt
O
 
 Koparir et al. (2010) prepared some new arylidene-amino compounds with 
Schiff base unit, 40(a-d), via the reaction of 4-amino-5-(4-pyridyl)-4H-1,2,4-
triazole-3-thione or 4-amino-5-(2-hydroxyphenyl)-4H-1,2,4-triazole-3-thione with a 
various aromatic aldehyde in anhydrous ethanol which was then converted into the 
corresponding Mannich base compounds, 41(a-d). It was reported that the thione-
thiol forms are two tautomers, whereby the first tautomer exists in pure solid form.  
X = a: H; b: 4-OMe; c: 4-OH, 3-OMe; d: 2,4-dihydroxy
NN
N
N
S
N
41(a-d)
H
X
NN
N
N
S
N
40(a-d)
H
X
H N O
 
 Abdel-Rahman et al. (2011) synthesised a new compounds of arylidene-amino 
compounds with Schiff base unit, 42(a-b) which then undergo cyclisation reaction to 
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form 3-(4-pyridyl)-6-aryl-7H-1,2,4-triazolo[4,3-b][1,3,4]thiadiazole, 43(a-b). 
However, no biological activity studies were reported for these compounds.  
NN
N S
N
NN
N
N
SH
N
43(a-d)
H
X F
X = a: F; b: Cl
N
X
F
42(a-d)
 
 Some new phenolic Schiff base compounds, 44(a-g) have been synthesised 
from 4-amino-5-(4-hydroxyphenyl)-4H-1,2,4-triazole-3-thiol, followed by a 
condensation reaction with aromatic carbonyl compounds in refluxing methanol in 
the presence of traces of glacial ethanoic acid. Treatment of these compounds with 
thioglycolic acid gave compounds 45(a-g) (Rajput, 2012).  
R = a: H; b: 2-Cl; c:4-Cl; d: 2,-CH3; e: 4-CH3; f: 2-OH; g: 2-NH2
NN
N
N
SH
45(a-g)
NN
N
N
SH
44(a-g)
H
R
HO
S
O
HO
H
R
 
 Other significant Schiff base compounds were reported by Sachdeva et al. 
(2013) with good anti-inflammatory activities. 5-thiol-3-(4-pyridyl)-4H-1,2,4-triazol-
4-yl-thiosemicarbazide, 46 was converted to 2-substituted-N-[3-(pyridin-4-yl)-5-
sulfanyl-4H-1,2,4-triazol-4-yl]hydrazinecarbothioamide compounds, 47(a–j) and  
48(a–e) via reaction of 46 with substituted aldehyde using the traditional technique 
and 1H-indole-2,3-di-ones using the microwave irradiation technique, respectively.  
 15 
R = a: H; b: 5-Cl; c: 5-Br; d: 5-CH3; e: 5-NO2
47(a-j)
NN
N
HN
SH
46
S
HN
N
N
NN
N
HN
SH
S
HN
N
N
NN
N
HN
SH
S
HN
N
NH2
H
X HN
O
R
48(a-e)
X = a: H; b: 4-NO2; c:2-Cl; d: 3-Cl; e: 4-Cl; f: 4-OCH3;      
g: 3,4,5-tri-OCH3; h: 3-OH; i: 3-OH, 4-OCH3; j: 4-F
 
 Some new compounds of 49(a-d), 50(a-d) and 51(a-d) can be obtained by 
refluxing the corresponding 4-amino-5-aryl-4H-1,2,4-triazole-3-thiol with 3-aryl-1H-
pyrazole-4-carbaldehyde compounds in the presence of few drops of sulphuric acid 
as a catalyst in ethyl alcohol solvent. All these targeted compounds have been 
evaluated as potent antibacterial, antifungal and analgesic agents (Vijesh et al., 
2013). 
Ar = a: 2,4-dichlorophenyl; b: 4-thioanisyl; c:2,5-dichlorothiophene d:biphenyl
49(a-d)
NN
N
N
SH
50(a-d)
H
N NH
Ar
O
NN
N
N
SH
H
N NH
Ar
N
NN
N
N
SH
H
N NH
Ar
N
H3C
51(a-d)
 
 Ding et al. (2010) reported an intermediate of potassium dithiocarbamate salt, 
52 which undergone a ring closure with a surplus of 85% hydrazine hydrate to 
produce a corresponding phenolic 1,2,4-triazole, 53, followed by the formation of 
Schiff base compounds, 54(a-h).   
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R = a: Ph; b: 4-F-Ph; c: 2-F-Ph; d: 4-Cl-Ph; e: 4-OCH3-Ph; 
f: 3-NO2-Ph; g: Ph-CH=CH-; h: 2-Furyl
52 53 54(a-h)
 
 
 Other potassium dithiocarbamate salts, 55(a-f) were reported by Gajera et al. 
(2012). Treatment of the salts with an excess of hydrazine monohydrate initiated the 
ring closure into the corresponding 1,2,4-triazole compounds, 56(a-f), followed by 
the condensation reaction to form the Schiff base compounds, 57(a-h). 
N
H
O
H
N S
S
K N
NHN
S
N
N
NHN
S
NH2
H
R = a: H; b: 2-NH2; c: 4-NH2; d: 4-NO2; e: 4-CH3; f: 4-Cl
R1/X = a: H/4-NO2; b: 2-NH2/4-NO2; c: 4-NH2/4-NO2; d: 4-NO2/2-
OH; e: 4-NO2/4-NO2; f: 4-CH3/4-NO2; g: 4-Cl/4-Cl; h: 4-Cl/4-OH
55(a-f) 56(a-f) 57(a-h)
R R
R1
X
 
 Wakale and Pattan (2015) reported a new Schiff base compounds of (E)-4-
(substituted methylene amino)-5-(2-hydroxyphenyl)-4H-1,2,4-triazole-3-thiol, 58-59 
via the synthesis pathway of 4-amino-1,2,4-triazole synthesis. Treatment of these 
compounds with thioglycolic acid in DMF produced two new series of 3-(3-(2-
hydroxyphenyl)-5-mercapto-4H-1,2,4-triazol-4-yl)-2-substituted-thiazolidine-4-one, 
60-61, respectively. All these compounds were tested for antimicrobial activity. The 
biological study showed that the new molecules 59, 60 and 61 exhibited the strongest 
inhibition against the microbial strains. 
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2.3 1,2,4-Triazolo[4,3-b][1,2,4]thiadiazole derivatives 
 A variety of 1,2,4-triazolo[4,3-b][1,2,4]triazole compounds have been 
synthesised and their biological activity being reported. El-Ashry et al. (2006) 
synthesised 3-(3-chlorobenzo[b]-2-yl)-6-(N,N-dimethylamino)-1,2,4-triazolo[3,4-
b][1,3,4]thiadiazole, 62 via microwave irradiation method. This technique was also 
used by Al-Abdullah et al. (2007) to synthesize 3-(1-adamantyl)-6-arylamino-1,2,4-
triazolo[3,4-b][1,3,4]thiadiazole compound, 63 which showed good antimicrobial 
activities. Sodium 1-(6-phenylamino-1,2,4-triazolo[3,4b][1,3,4]thiadiazole-3-
yl)heptadecane-1-sulfonate, 64 with good antibacterial activity was prepared by El-
Sayed (2006).    
NN
N
S
N
NHPh
64
NN
N
S
N
N(CH3)2
62
S
Cl NN
N
S
N
NHAr
63
CH3(CH2)15 CH
SO3Na
 
 Compounds with a similar scaffold of novel 1,2,4-triazolo[3,4-
b][1,3,4]thiadiazole derivatives were reported by several groups. Salih (2008) 
reported the preparation and characterisation of 3-mercapto-6-amino-1,2,4-
triazolo[3,4-b][1,3,4]thiadiazole, 65 while Shrivastava et al. (2010) reported 3-(2-(4-
isobutylphenyl)propyl)-6-phenyl amine[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole, 66 
with their good screening results as antimicrobial, analgesic and anthelmintic 
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activities. Al-Omar (2010) reported the synthesis of 3-(2-thienyl)-6-(4-sub-
phenylamine)-[1,2,4]triazolo[3,4-b][1,3,4] thiadiazole, 67 via microwave irradiation 
technique and their antimicrobial activity. 
NN
N S
N
NHC6H566
NN
N S
N
NH
67
NN
N S
HS
N
NH2
65
S X
X = H,3-F, 4-F, 4-Cl, 4-Br  
 Other novel compounds encompassing of 1,2,4-triazole and 1,3,4-thiadiazole 
were also synthesised and characterised. Omprakash et al. (2011) reported a new 
compound of N-phenyl-3-(pyridin-3-yl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-6-
phenyl amino, 68 having good antimicrobial activity. Abdel-Rahman et al. (2011) 
have reported new derivative of 3-(pyrid-4-yl)-6-phenylamino-1,2,4-triazolo[4,3-
b][1,3,4]thiadiazole, 69, showing anti-inflammatory and antimicrobial activities. 
Pandeya et al. (2012) synthesised two derivatives, 70 of 3(4-nitrophenyl)-N-
phenyl[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-phenyl amino and 3(phenyl)-N-
phenyl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole-6-phenyl amino with their antifungal 
and antibacterial activities. Harcharan et al. (2012) have reported a new compound of 
3-(3-bromophenyl) [1,2,4]-triazolo[3,4-b][1,3,4]thiadiazol-6-amine, 71, which was 
then converted to the corresponding new Schiff base compounds, 72. All these 
compounds showed good antibacterial and antifungal activities.  
NN
N S
N
NHPh
N
NN
N S
N
NHPh
NN
N S
N
NHPh
N
X
68 7069
X = H, NO2
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2.4 1,2,4-Triazolo[4,3-b][1,2,4]triazole derivatives 
 A new system of fused 1,2,4-triazolo-triazole derivative such as  3-(pyridin-4-
yl)6-amino-7H-1,2,4-triazolo[4,3-b][1,2,4]triazole was reported by Abdel-Rahman et 
al. (2011). The compound showed promising results for anti-inflammatory and 
antimicrobial activities. 
NN
N NH
N
NH2
N
73  
 
2.5 1,2,4-Triazolo-3-thiolate derivatives 
 In this interesting study, Chemica et al. (2011) reported the interaction of 4-
amino-5-(4-pyridyl)-4H-1,2,4-triazole-3-thiol, 74 with a cyclic secondary amines 
such as pyrrolidine and morpholine in anhydrous dimethyl sulfoxide formed the 
corresponding quaternary salts of pyrrolidinium 4-amino-5-(pyridin-4-yl)-4H-1,2,4-
triazole-3-thiolate, 75 and morpholine-4-ium 4-amino-5-(pyridin-4-yl)-4H-1,2,4-
triazole-3-thiolate, 76, respectively. Similar reactions of N-(3-mercapto-5-(4-
pyridyl)-4H-1,2,4-triazol-4-yl) isonicotinamide, 77 with morpholine and pyrrolidine 
yielded the quaternary salts of pyrrolidinium 4- isonicotinamido-5-(pyridin-4-yl)-4H-
1,2,4-triazole-3-thiolate, 78 and morpholine-4-ium 4- isonicotinamido-5-(pyridin-4-
yl)-4H-1,2,4-triazole-3-thiolate, 79, respectively. These new salts were screened for 
their antibacterial and antifungal activity. 
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2.6 1,3,4-Oxadiazole-2-thiolate derivatives 
 Rutavicius et al. (2003) have also reported the interaction of 5-(4-pyridyl)-
1,3,4-oxadiazole-2-thiol with piperidine or morpholine in dimethylformamide under 
reflux. The equivalent ratio of piperidine or morpholine in the solvent undergo 
cleavage of oxazole ring but in the presence of excess piperidine or morpholine in 
dimethyl sulfoxide, piperidinium 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-thiolate, 80 and 
morpholin-4-ium 5-(pyridin-4-yl)-1,3,4-oxadiazole-2-thiolate, 81, were formed, 
respectively.   
NN
O SN
80
NN
O SN
81
H2N OH2N
 
 
 
 
